Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1+
Abstract
Ovarian clear cell carcinoma (OCCC) is a rare histologic subtype of epithelial ovarian cancer, accounting for approximately 5%–10% of cases in Western populations. Compared with high-grade serous ovarian cancer, OCCC is characterized by lower sensitivity to conventional cytotoxic chemotherapy and consequently poor outcomes. Given the limited efficacy of standard systemic therapies, there is a considerable unmet need for novel treatment strategies in OCCC. Antibody–drug conjugates (ADCs) have emerged as a promising therapeutic class across several solid tumors. Among these agents, trastuzumab deruxtecan (TDXd) has demonstrated substantial clinical activity in HER2-expressing malignancies and has recently shown efficacy across multiple tumor types in the DESTINY-PanTumor02 trial, but with low evidence in OCCC. Here, we report a patient with heavily pretreated recurrent ovarian clear cell carcinoma who achieved a durable and clinically meaningful response to trastuzumab deruxtecan despite low HER2 expression (IHC 1+).
Related
- ERBB2 Exon 20 Mutation-Guided Trastuzumab Deruxtecan Therapy in Metastatic Lung Adenocarcinoma with Low HER2 Expression: A Case Report.
- Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
- From Lethargy to Recovery: Central Diabetes Insipidus from Pituitary Metastasis in Recurrent HER2-Positive Breast Cancer Treated with Fam-Trastuzumab Deruxtecan-Nxki
- Nationwide HER2 Testing, Prospective Trastuzumab-Based Therapy, and Deep Visual Proteomics in Esophageal Squamous Cell Carcinoma
- Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report
BibTeX
@article{wolfrum2026case,
title = {{Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1+}},
author = {Angelika Wolfrum and Julia Ladurner and Burghard Abendstein},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1856710},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1856710},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1+
AU - Angelika Wolfrum
AU - Julia Ladurner
AU - Burghard Abendstein
PY - 2026
DA - 2026/11/03
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1856710
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1856710
AB - Ovarian clear cell carcinoma (OCCC) is a rare histologic subtype of epithelial ovarian cancer, accounting for approximately 5%–10% of cases in Western populations. Compared with high-grade serous ovarian cancer, OCCC is characterized by lower sensitivity to conventional cytotoxic chemotherapy and consequently poor outcomes. Given the limited efficacy of standard systemic therapies, there is a considerable unmet need for novel treatment strategies in OCCC. Antibody–drug conjugates (ADCs) have emerged as a promising therapeutic class across several solid tumors. Among these agents, trastuzumab deruxtecan (TDXd) has demonstrated substantial clinical activity in HER2-expressing malignancies and has recently shown efficacy across multiple tumor types in the DESTINY-PanTumor02 trial, but with low evidence in OCCC. Here, we report a patient with heavily pretreated recurrent ovarian clear cell carcinoma who achieved a durable and clinically meaningful response to trastuzumab deruxtecan despite low HER2 expression (IHC 1+).
SN - 2234-943X
ER -